Form D · Biotechnology
EmboMedics, Inc.
Minneapolis, MN · CIK 0001592901
Offering snapshot reported Oct 25, 2017 · SEC filing
- Reported sold
- $741K Offering amount: $1.3M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 20, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 25, 2017 | Initial | $740,775 | No comparison | 12 | SEC filing |
| Apr 7, 2016 | Amendment | $4,287,938 | $3,441,188vs Aug 14, 2014 | 29 | SEC filing |
| Aug 14, 2014 | Initial | $846,750 | No comparison | 9 | SEC filing |
| Feb 3, 2014 | Initial | $860,000 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-297421
Convertible promissory notes and equity securities issuable upon conversion of such Notes.
Source: Form D, filed Oct 25, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kraig Black | Director |
| Robert Cohen | Director, Executive |
| Jon Freeman | Executive |
| Jafar Golzarian | Director, Promoter |
| Robert Halverson | Director |
| Reza Malek | Director |
| Omid Souresrafil | Director, Executive, Promoter |
| Gerald D. Van Eeckhout | Director |
| Lihui Weng | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
678 Mendelssohn Ave. N.
Minneapolis, MN, 55427
Minneapolis, MN, 55427